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Abstract: Background: Cellular reprogramming is a stressful process, which requires cells to
engulf somatic features, produce and maintain stemness machineries. Autophagy is a
process to degrade unwanted proteins and required for the derivation of induced
pluripotent stem cells (iPSCs). However, the role of autophagy during iPSC
maintenance remains undefined.
Methods: Human iPSCs were investigated by microscopy, immunofluorescence and
immunoblotting to detect autophagy machinery. Cells were treated with Rapamycin to
activate autophagy and Bafilomycin to block autophagy during iPSC maintenance.
High concentrations of Rapamycin treatment, unexpectedly, resulted in spontaneous
formation of round floating spheres of uniform size, which were analyzed for
differentiation into three germ layers. Mass spectrometry was deployed to reveal
altered protein expression and pathways associated with Rapamycin treatment.
Results: We demonstrate that human iPSCs express high basal levels of autophagy,
including key components of APMKα, ULK1/2, BECLIN-1, ATG13, ATG101, ATG12,
ATG3, ATG5 and LC3B. Block of autophagy by Bafilomycin induces iPSC death and
Rapamycin attenuates the Bafilomycin effect. Rapamycin treatment up-regulates
autophagy in iPSCs in a dose/time-dependent manner. High concentration of
Rapamycin reduces NANOG expression and induces spontaneous formation of round
and uniformly sized embryoid bodies (EBs) with accelerated differentiation into three
germ layers. Mass spectrometry analysis identifies actin cytoskeleton and adherens
junctions as the major targets of Rapamycin in mediating iPSC detachment and
differentiation.
Conclusions: High levels of basal autophagy activity are present during iPSC derivation
and maintenance. Rapamycin alters expression of actin cytoskeleton and adherens
junctions, induces uniform EB formation and accelerates differentiation. IPSCs are
sensitive to enzyme dissociation and require lengthy differentiation time. The shape
and size of EBs also play a role in the heterogeneity of end cell products. Therefore,
this research highlights the potential of Rapamycin in producing uniform EBs and in
shortening iPSC differentiation duration.
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Response to Reviewers: Point-to-point Response
Reviewer reports:
Reviewer #1: This is an interesting investigation into the role of autophagy in iPSC
function, and builds on the growing body of work demonstrating the key role of
autophagy in stem cell biology. The authors show a higher level of autophagy at basal
conditions in iPSCs over their parental fibroblasts, which can be modulated in a dose-
dependent manner with rapamycin to affect the iPSC maintenance in culture and EB
formation/differentiation over time.
RESPONSE: We thank Reviewer #1 for careful reading and recognition of the key
points of the manuscript.
General comments:
-       The English in the manuscript would benefit from revision. Several areas are in
need of editing for clarity, and there are a high number of errors/typos throughout the
manuscript.
RESPONSE: We apology for the errors/typos in the previous versions. The Manuscript
has now been gone through several edits and hope the revised version is substantially
improved.
-       Avoid including discussion of the results in the Results section (e.g. discussion of
the results in Fig 2)
RESPONSE: The introductory contents in section 2 and 3 of the Results on pages 11-
12 are now shortened.
Specific comments:
I appreciated the demonstration of high LC3II levels across four separate donors in the
iPSC population. I would perhaps suggest including LC3I levels at least in the blot in
2E to show whether there is an upregulation of autophagosome accumulation/cycling,
or a block in autophagosome degradation that causes the shift. Some recent studies
have shown stem cell populations to have very low degrees of autophagosome cycling
at a basal state.
RESPONSE: We acknowledge that The Reviewer #1 brought up an interesting point of
the autophagosome cycling. This manuscript has addressed several points: high level
of the autophagy is crucial for iPSC physiology and maintenance, and induced
autophagy by Rapamycin is associated with cell detachment and EB formation
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
together with accelerated differentiation.
In the revised version, we have new data to further strengthen the importance of
autophagy in iPSCs, that block of autophagy by Bafilomycin induces cell death and
Rapamycin rescues Bafilomycin-induced cell death (See Lines 303-320 and new
Figure 5). We also provide new mechanistic data for accelerated differentiation that
Rapamycin downregulates NANOG expression in a concentration-dependent manner
(See Figure 8L-M, and lines 355-362, 767-771).
We kept the original Figure 2 which was done on 10% SDS-PAGE. The data showed
that (1) Rapamycin can induce autophagy in both iPSCs and fibroblasts, and (2) both
the basal and induced autophagy activities are higher in iPSCs. We have now provided
a Supplemental Figure 1 to show that two bands of LC3B-I (16kD) and LC3B-II (14kD)
can be better resolved on 15% SDS-PAGE. The new data brought up an interesting
point that Rapamycin increased LC3B-I rather than LC3B-II expression in fibroblasts
(Supplemental Figure 1), and this is different from iPSCs (see Figure 4), and will
require further investigation and is therefore provided as a Supplemental Figure, to
avoid diversion of the focus. See Line 299-301.
: The overall goal of this figure seems to be to show high levels of autophagy signaling
molecules across several iPSC lines. Demonstrating the activation of autophagy
signaling is important, but it is difficult to discern levels of activation with no outside
standard for comparison in this figure (all relative abundance measurements are made
using each individual sample as its own control). I would suggest including a lane or
two of parental fibroblasts or other control cells to serve as a comparison as you did in
Figure 2.
RESPONSE: We appreciate Reviewer #1’s comments, carried out new experiments
and included new data in the revised Figure 3H. Consistent with other data shown in
the manuscript, both ATG5 and ATG12 are more abundant in iPSCs than that in
parental fibroblasts. See revised Figure 3H and lines 280-283
It is also unclear why samples a-e are assayed for ATGs but not f-l. Error bars are
missing from Fig 3G.
RESPONSE: This reflected the history of iPSC availability in the group. We first carried
out series of WB on 5 lines (a-e, see Figure 3A-B) with three repeated blots. When
additional 7 iPSC lines “f-l” became available, we further strengthen the point by using
iPSC line “b” as a reference in the new Western blots. These lines were done only
once (Figure 3C and G), but the data were consistent with 5 lines in A-B, Figure
3A,B,D-F.
Fig 5/6: Results investigating the iPSC maintenance focus solely on the rapamycin
dosing. Inhibition of autophagy with bafilomycin or another treatment is not discussed
in this study much. If rapamycin benefits iPSC maintenance and differentiation, how
does inhibiting the pathway affect things? Some studies on stem cell autophagy have
shown conflicting roles of rapamycin and bafilomycin treatments on the function of
autophagy.
RESPONSE: We appreciate Reviewer #1 for expert opinion. We carried out additional
experiments with bafilomycin A1 as suggested. The new data showed that bafilomycin
induced dose-dependent cell death whereas Rapamycin can rescue Bafilomycin-
induced cell death (See lines 303-320 and new Figure 5). This further highlights the
importance of autophagy in iPSCs.
Fig 8: Given that the authors showed an optimal Rapamycin response of 200 nM in Fig
4 and used this dose for subsequent EB experiments in Figs 5-7, it is unclear why 50
and 100 uM doses are used in this experiment, which are substantially higher doses.
RESPONSE: Apology for the typos. we used 50 and 100 nM (not uM)  in proteomics
assays.
Discussion: The discussion focuses largely on results from Fig 8, which seems minor
compared to the rest of the manuscript that focuses on the specific autophagic
character and response in the iPSCs examined here. Some points for consideration in
the discussion:
-       Fig 2 shows two donors having different basal levels of autophagy (a/b vs c/d).
How will donor variability affect these results, or even different iPSC parent sources?
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
-       Do the authors feel that a particular set of culture conditions here are suitable for
recommended use in standard iPSC culture? How should rapamycin be used most
efficiently to benefit iPSC maintenance, differentiation, etc?
-       EBs assayed in Fig 7 show a high level of LC3-I compared to the control EBs.
Speculation as to why? How does the basal level of cytosolic LC3/autophagosome
cycling and accumulation affect this function of iPSCs?
RESPONSE: many thanks to Reviewer 1 for constructive advice. We revised
Discussion accordingly
Reviewer #2: The manuscript by Sotthibundhu A and colleagues describes that
inhibition of mTOR signaling pathway by rapamycin could regulates autophagy and cell
adhesion in induced pluripotent stem cells. The group highlights that the potential of
rapamycin in producing uniform embryoid bodies and in accelerating iPSCs
differentiation.
Overall, the manuscript is interesting and will contribute to the current understanding of
iPSCs biology. It is of particular interest and may encourage further studies into this
area about the role of autophagy during iPSC maintenance. However, the work as
developed is largely confirmatory of previous findings and while there is some new
information, such is limited. For example, it is well established that autophagy could be
regulated by mTOR pathway, and regulation of embryoid body formation by mTOR
pathway was also reported (Oncogene 2010).
RESPONSE: We thank Reviewer #2 for bringing up this literature, which is different
from our data with different cell types. The paper is cited as Ref 40 and discussed in
lines 413-416 .
My critiques:
1.      In figure 1A, images showing autophagic vacuoles of fibroblasts without
reprogramming should also be shown. In panel H-K, its better to show the
colocalization of autophagy, lysosome, Golgi and ER markers in the same cell
RESPONSE: Thank Reviewer #2 for constructive comments. We now added a bright
field image of fibroblasts in new Figure 1F. We carried out double staining as
suggested and included in new Figure 1C,D,G,H.
2.      In figure 2F&G, it seems that LC3BII in iPSCs showed similar increase (about 2.5
folds) that fibroblasts, no matter the cells were treated with rapamycin or not. How it
can be concluded that autophagy is rapamycin-inducible?
RESPONSE: Figure 2F showed the difference of basal LC3B between fibroblasts and
iPSCs. Figure 2G showed relative LC3B activity between fibroblasts and iPSCs after
Rapamycin treatment. Rapamycin can induce LC3B in both fibroblasts and iPSCs. See
lines 255-265.
3.      In figure 3, the results of fibroblasts as negative control should also be shown.
RESPONSE: Thank Reviewer #2 for the suggestion. I have now included new data on
Figure 3H, showing ATG5 and ATG12 are higher in iPSCs than in fibroblasts.
4.      The figure 5F and figure 6E are the same image, please change either of them
RESPONSE: Many thanks to Reviewer #2 for careful reading. We have now removed
the duplicated image, see revised Figure 7.
5.      What's the difference among figure 7J, K and L?
RESPONSE: Many thanks. We have now removed K and L, and added new
mechanistic data of reduced NANOG expression by Rapamycin treatment see revised
Figure 8.
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Abstract  25 
Background: Cellular reprogramming is a stressful process, which requires cells to engulf 26 
somatic features, produce and maintain stemness machineries. Autophagy is a process to 27 
degrade unwanted proteins and required for the derivation of induced pluripotent stem cells 28 
(iPSCs). However, the role of autophagy during iPSC maintenance remains undefined.  29 
Methods: Human iPSCs were investigated by microscopy, immunofluorescence and 30 
immunoblotting to detect autophagy machinery. Cells were treated with Rapamycin to activate 31 
autophagy and Bafilomycin to block autophagy during iPSC maintenance. High concentrations 32 
of Rapamycin treatment, unexpectedly, resulted in spontaneous formation of round floating 33 
spheres of uniform size, which were analyzed for differentiation into three germ layers. Mass 34 
spectrometry was deployed to reveal altered protein expression and pathways associated with 35 
Rapamycin treatment.  36 
Results: We demonstrate that human iPSCs express high basal levels of autophagy, including 37 
key components of APMKα, ULK1/2, BECLIN-1, ATG13, ATG101, ATG12, ATG3, ATG5 38 
and LC3B. Block of autophagy by Bafilomycin induces iPSC death and Rapamycin attenuates 39 
the Bafilomycin effect. Rapamycin treatment up-regulates autophagy in iPSCs in a dose/time-40 
dependent manner. High concentration of Rapamycin reduces NANOG expression and induces 41 
spontaneous formation of round and uniformly sized embryoid bodies (EBs) with accelerated 42 
differentiation into three germ layers. Mass spectrometry analysis identifies actin cytoskeleton 43 
and adherens junctions as the major targets of Rapamycin in mediating iPSC detachment and 44 
differentiation. 45 
Conclusions: High levels of basal autophagy activity are present during iPSC derivation and 46 
maintenance. Rapamycin alters expression of actin cytoskeleton and adherens junctions, 47 
induces uniform EB formation and accelerates differentiation. IPSCs are sensitive to enzyme 48 
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dissociation and require lengthy differentiation time. The shape and size of EBs also play a role 49 
in the heterogeneity of end cell products. Therefore, this research highlights the potential of 50 
Rapamycin in producing uniform EBs and in shortening iPSC differentiation duration.  51 
 52 
Key words 53 
Actin cytoskeleton, Adherens junctions, Autophagy, Differentiation, Embryoid Body, Induced 54 
Pluripotent Stem Cells, Rapamycin 55 
 56 
Background 57 
The induced pluripotent stem cell (iPSC) technology enables conversion of patient’s somatic 58 
cells into embryonic stem (ES)-like cells [1], which can be differentiated into the major cell 59 
types in the body, raising the expectation of personalized medicine to treat patients with own 60 
somatic tissue-derived cells. This also offers an opportunity to generate human cell models of 61 
diseases for therapeutic development, which has not kept pace with pharmaceutical investment in 62 
recent decades. A major impediment to drug discovery is attributable to the lack of suitable 63 
disease models of human origin, as species differences may totally affect drug efficacy [2]. Some 64 
disease pathologies are shown to be re-capitulated in the culture dish. For example, many 65 
patient-specific iPSCs have been generated to investigate disease progression in vitro and 66 
disease-related phenotypes are partially preserved in iPSC-derived cells [3-6]. Recent successes 67 
in the growth of “mini-organ”, i.e., 3D retina [7-8] and cerebral organoids [9], may provide 3-D 68 
human disease models. However, there are challenges in phenotyping iPSCs prior to the 69 
development of screening assays, which include lengthy differentiation durations and 70 
heterogeneity of the end cell products. 71 
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The differentiation, survival and self-renewal of human stem cells can be regulated by a 3D 72 
microenvironment including shape and size [7-9,10]. Human iPSCs are hyper-sensitive to cell 73 
dissociation reagents, and seconds of exposure to Trypsin/EDTA may lead to failure of iPSC 74 
adhesion or survival. Consequently, many laboratories adopt “cut-and-paste” method to 75 
mechanically passage iPSCs, which results in EBs of uncontrollable sizes with irregular shapes, 76 
which may potentially contribute to the heterogeneity. The differentiation of mature cell types 77 
from human iPSCs is also time-consuming. For example, 3~5 months are required to generate 78 
functional neurons, astrocytes or oligodendrocytes [11-13]. Therefore, accelerated differentiation 79 
remains to be optimized.  80 
Efforts have been made to improve the reprogramming efficiency, and autophagy, a process to 81 
degrade unwanted proteins, is found as one of the regulators during cellular reprogramming [14-82 
15]. Autophagy is conserved from yeast to mammals, and is generally induced by intra- and 83 
extra-cellular stress. Upon induction, the preautophagosomal structure is formed and elongated 84 
to form a phagophore, which engulfs cytoplasmic components, leading to the formation of 85 
autophagosomes with double membranes. The genes involved in the autophagy are termed 86 
Autophagy-Related Genes (ATGs), and >12 ATGs have been identified. They regulate 87 
autophagosome formation through two evolutionarily conserved ubiquitin-like conjugation 88 
systems, the ATG12-ATG5 and the ATG8 (LC3)-PE (phosphatidylethanolamine) systems [16]. 89 
The LC3B-I (microtubule-associated proteins 1A/1B light chain 3-I) is conjugated with PE to 90 
become LC3B-II, which associates with both the outer and inner membranes of the 91 
autophagosome. After fusion with the lysosome, the autolysosome is degraded [17]. In mice, 92 
Atg3, Atg5 and Atg7 are essential for reprogramming of mouse embryonic fibroblasts [14-15]. 93 
Cells lacking Atg3, Atg5 or Atg7 abrogated iPSC colony formation [15].  94 
The autophagy pathway can be activated by AMPK signaling, but is normally inhibited by the 95 
mammalian target of the Rapamycin (mTOR) pathway. The presence of hyperactivated mTOR 96 
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activity in Tsc2-/- somatic cells completely blocked reprogramming [14]. Consistent with this, 97 
Rapamycin - an inhibitor of the mTOR pathway at 0.3-1 nM could increase reprogramming 98 
efficiency by 2~3 folds [18]. In addition, 0.1 nM of PP242, a selective inhibitor of 99 
mTORC1/mTORC2 binding at the ATP domain, also increased reprogramming efficiency by 5-100 
folds [18]. Other compounds associated with autophagy such as PQ401- an IGF1 receptor 101 
inhibitor and LY294002 - an inhibitor of PI3K also increased reprogramming by 4-folds [18]. 102 
Mechanistically, mTOR is regulated by SOX2, one of the four reprogramming factors. SOX2 103 
can physically bind to the mTOR promoter and repress mTOR expression thereby activate 104 
autophagy [15]. Therefore, an appropriate level of autophagy is required for cell reprogramming. 105 
However, roles of autophagy in iPSC maintenance and differentiation remain elusive. 106 
In this study, we showed the presence of high levels of basal autophagy activity during iPSC 107 
reprogramming and maintenance. Rapamycin alters expression of adherens junctions and actin 108 
cytoskeleton, induces iPSC detachment, and results in uniform EB formation. Rapamycin 109 
treatment also accelerates differentiation of human iPSCs into three germ-layers.  110 
 111 
Methods 112 
iPSC derivation 113 
On day 0, human fibroblasts were seeded at a density of 2.0x104 cells/well on a 6-well dish. Next 114 
day, cells were transduced with a polycistronic (OKSM) lentivirus containing four 115 
reprogramming factors (SCR544- Human STEMCCA constitutive lentivirus reprogramming kit, 116 
Millipore, SCR544) in 700 µl of fibroblast medium, supplemented with 4µg/ ml polybrene 117 
(Millipore, TR-1003). On day 2, cells were repeatedly transduced with lentivirus. The medium 118 
was then replaced daily with complete fibroblast medium supplemented with 0.25 mM sodium 119 
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butyrate (NaB, Sigma, 156-54-7) for 4 days. On day 6, 6-well dishes were pre-seeded with γ-120 
irradiated MEF (VH Bio Limited, 07GSC6001G) at a density of 1.5x105 cells/well. On day 7, 121 
transduced cells were trypsinized with 0.25% Trypsin/EDTA, and replated onto pre-seeded MEF 122 
dishes at a density of 3.0x104 cells/well, and cultured in KO iPSC medium supplemented with 123 
10ng/ml bFGF (Peprotech, 100-18B) plus 0.25 mM NaB. The medium was changed every other 124 
day. The addition of NaB was discontinued after day 20. 125 
Individual iPSC colonies began to emerge after day 14 and were picked up on day 28, 126 
mechanically dissociated into smaller pieces by pipetting and plated into γ-MEF coated 12-well 127 
plates. Selected clones were characterized using alkaline phosphatase activity, RT-PCR and 128 
immunoblotting to detect endogenous expression of OCT4, SOX2 and NANOG, and 129 
immunocytochemistry to detect surface markers of SSEA4, TRA 1-60 and TRA 1-81 in addition 130 
to the transcription factors (StemLightTM pluripotency antibody kit, cell signaling, 9656).  131 
Cell culture 132 
Human iPSC lines were maintained on a feeder-free culture system. The 6-well plates were 133 
pre-coated with Geltrex, LDEV-free hESC qualified reduced growth factor basement 134 
membrane matrix (Invitrogen, A1413302). Geltrex was thawed overnight at 4˚C and diluted 135 
1:100 in KO-DMEM medium (Invitrogen, 10829018). Each well was coated with 1.5 ml 136 
Geltrex, incubated for one hour at 37˚C, and was then replaced with the mTeSR1 medium 137 
(StemCell Technologies, 05850) with 10 ng/ml bFGF at 37°C and 5% CO2. iPSCs were cut 138 
and paste into Geltrex-coated wells. The medium was renewed daily and passaged every 6 139 
days. Then, chemicals such as Rapamycin were added to respective experiments.  140 
For induction of autophagy signaling, iPSC colonies were cultured in mTeSR1 medium 141 
supplemented with 0-300 nM Rapamycin (Sigma, R8781) for 1-9 days. For autophagic flux 142 
assay, human iPSCs were treated with 200 nM Rapamycin in the absence or presence of 50 143 
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nM Bafilomycin A1 for 24 hrs (Sigma, B1793) as specified. Cells were collected and protein 144 
was subsequently analyzed by immunoblotting. 145 
EB formation by cut-and-paste method 146 
The cut-and-paste method was deployed to make conventional EBs as iPSCs. Spontaneously 147 
differentiated cells were removed under a stereomicroscope inside the culture safety cabinet, 148 
and fresh medium was added to the remaining iPSC colonies, which were cut into small 149 
pieces with 10ul pipette tip. The iPSC sections were then scraped off the dish and transferred 150 
to a T25 flask in 15ml EB medium (KO DMEM, KO serum, 1X L-glut and 1X NNEA plus 151 
50ul beta-mercaptoethanol). The medium was changed every other day, and the EBs were 152 
cultured for 7-10 days before plating out for spontaneous differentiation assays. 153 
Antibodies and reagents 154 
The reagents for TEM include Sodium cacodylate (C0250, Sigma), low viscosity resin kit 155 
(AGR1078A, Agar Scientific) and 2 % osmium tetroxide (AGR1016, Agar Scientific), 25 % 156 
Glutaraldehyde Solution (23114.02, AMSBIO), and thermanox plastic coverslips (NUNC). 157 
For immunocytochemistry, following antibodies were used: anti-LAMP1 (25630), anti-158 
Syntaxin-6 (12370), and anti-NESTIN (105389) from Abcam; SelectFX® Alexa Fluor® 488 159 
Endoplasmic Reticulum labeling kit (S34200) from Life Technologies; anti-LC3B from 160 
autophagy antibody sampler kit (4445), Alexa Fluor® 488 Goat Anti-Rabbit IgG fluorescent 161 
dye (4412), and Alexa Fluor® 555 Goat Anti-Mouse IgG fluorescent dye (4409) from Cell 162 
Signaling Technology. For immunoblot experiments, reagents included anti-α-fetoprotein 163 
(A8452), anti-α-smooth muscle actin (A2547), anti-ATG13 (SAB3500502) and ATG101 164 
(SAB3500503) from Sigma; anti-βIII tubulin (G7121) from Promega Corporation; anti-165 
ULK2 (56736) from Abcam; anti-LC3B, anti-BECLIN-1, anti-ATG5 from Cell Signalling 166 
Technology (D1G9; #8540P, 1:1000) anti-ATG12, and anti-ATG3 from autophagy antibody 167 
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sampler kit (4445), anti-p-ULK1(Ser317, 6887), anti p-p70 S6K (Thr389, 9205), anti-β-Actin 168 
(4967), HRP-conjugated anti-mouse IgG antibody (7076) and HRP-conjugated anti-rabbit-169 
IgG antibody (7074) from Cell Signaling Technology. MitoGreen (a Green-fluorescent 170 
mitochondrial dye) was purchased from Promokine (PK-CA707-70054). 171 
Transmission electron microscopy (TEM) 172 
iPSCs were cultured on Thermanox coverslips in 6-well plates coated with Geltrex, rinsed with 173 
prewarmed (37oC) 0.1M cacodylate buffer, fixed with 2% Glutaraldehyde and 2% 174 
Paraformaldehyde in 0.1M cacodylate buffer for 3 hours at room temperature, rinsed again with 175 
cacodylate buffer and post-fixed with 1% osmium tetroxide in cacodylate for 1hr at room 176 
temperature. Samples were then rinsed with cacodylate buffer, dehydrated through a series of 177 
graded ethanol, embedded in low viscosity resin according to the standard protocol, and 178 
polymerized at 60oC for 48hrs. Ultra-thin sections were obtained using a diamond knife, on a 179 
Leica Reichert Jung ultra-microtome, and stained with the contrasting agents, uranyl acetate and 180 
lead citrate, in a Leica EM AC20 stainer. Sections were examined with a Hitachi H7000 181 
transmission electron microscope fitted with a 1K Hamamatsu Digital Camera and images were 182 
captured using AMTV542 Image Capture Engine software. 183 
Immunocytochemistry 184 
To investigate the effect of Rapamycin, iPSC colonies or the embryoid body-like spheres were 185 
transferred to µ-Slide 8-well glass bottom (ibidi GmBH, 80826) coated with Geltrex. Cells were 186 
fixed with 4% paraformaldehyde for 10 min at room temperature and washed with PBS 3 times 187 
before permeabilization using 0.5% Triton X-100 for 10 min. Non-specific binding was blocked 188 
with 5% normal goat serum in PBS containing 0.5% Trion X for 1hr prior to incubation with 189 
primary antibodies overnight at 4˚C. The wells were washed three times with PBS and incubated 190 
with secondary antibodies for 1hr at room temperature. The nuclei were visualized by Hoechst 191 
counterstaining for 10 min. After washing with PBS, the immunofluoresence was visualized with 192 
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the Andor Revolution spinning disk confocal microscope, using Andor IQ2 software. The 193 
samples were imaged using a combination of λ405nm, λ488nm and λ564nm lasers. 194 
Immunoblotting 195 
Following experimental treatments, cell pellets were resuspended in NP40 cell lysis buffer 196 
(Invitrogen, FNN0021) supplemented with protease inhibitor cocktail (Sigma, P2714). Lysate 197 
was then centrifuged at 13,000 rpm for 10 min at 4°C, and the supernatant was collected and 198 
used for immunoblotting. Protein concentration was determined and the samples were denatured 199 
in sample buffer (62.5 mM Tris–HCl pH 6.8, 2% SDS, 10% glycerol, 2% mercaptoethanol and 200 
0.01% bromophenol blue) at 95°C for 5 min. Proteins were resolved on 10-15% SDS–PAGE 201 
gels and then electrophoretically transferred to a polyvinylidene difluoride (PVDF) membrane 202 
(Bio-Rad, 162-0177). The transfer efficiency was checked by Ponceau-S red staining (Sigma, 203 
P7170). The membranes were washed with Tris-buffered saline containing 0.1% Tween-20 204 
(TBST) for 5 min, incubated in blocking buffer for 1hr at room temperature and incubated 205 
overnight at 4°C with primary antibodies. They were then washed three times for 5 min each 206 
with TBST, incubated with secondary antibodies for 1hr at room temperature and washed in 207 
TBST. Finally, the membranes were visualized by enhanced chemiluminescence using ECLTM 208 
Prime (Amersham Biosciences, GZ28980926). The immunoblot band densities were normalized 209 
with its unphosphorylated protein or Actin or GAPDH, and quantified using a densitometer in 210 
the Scion image analysis program (National Institutes of Health, Bethesda, MD, USA). 211 
Data analysis and statistical methods 212 
Data were expressed as the mean ± SEM or mean ± SD as indicated. Significance was assessed 213 
using one-way analysis of variance (ANOVA) followed by the Tukey–Kramer test using 214 
GraphPad Prism version 5. p<0.05 was considered significant (*), p<0.01 very significant (**). 215 
Mass spectrometry analysis 216 
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The iPSCs were lysed in 1% SDS and the lysates were processed by using the FASP protocol as 217 
previously published [19]. Briefly, the cell lysates were sonicated, detergents removed by 218 
sequential washes in spin columns and proteins digested with trypsin. The peptides were 219 
analyzed on Q-Exactive Mass Spectrometer as previously described [20]. The proteins were 220 
identified and quantified with the MaxQuant 1.5 software suite by searching against the human 221 
uniprot database, with N-terminal actylation and methionine oxidation as variable modification 222 
and a FDR of 0.01. Mass accuracy was set a 4.5 ppm for the MS and 20 ppm for the MS/MS. 223 
LFQ was performed by MaxLFQ as described [21]. One-way ANOVA was carried out to 224 
compare Rapamycin treated samples with control iPSCs. The mean expression levels (M) and 225 
standard error of means (SEM) were quantified, and folds of changes in the treated samples were 226 
calculated against the control iPSCs (set as 1). p<0.05 was considered statistically significant. A 227 
total of 220 proteins which were significantly altered after Rapamycin treatment were analyzed 228 
by the STRING program for pathway using GO Biological processes and GO cellular 229 
components.  230 
 231 
Results 232 
Autophagy is a prominent feature of reprogramming cells and stable iPSCs 233 
The autophagy-lysosome and ubiquitin-proteasome systems are the two major pathways that 234 
cells employ to selectively target long-lived and misfolded proteins, protein aggregates, damaged 235 
mitochondria, or unwanted cytoplasmic components and organelles [22]. We observed large 236 
autophagic vacuoles in the majority of cells during early reprogramming (red arrowheads, Figure 237 
1A). In young passages of stable iPSCs, autophagic vacuoles were abundantly present but 238 
reduced in size (red arrowheads, Figure 1B). However, large autophagic vacuoles were absent in 239 
parental fibroblasts (Figure 1F). TEM revealed the presence of lysosomal structures (blue 240 
arrowheads, Figure 1E,I) in iPSCs. Structures of endosomal/lysosomal nature with double 241 
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membranes were clearly evident under high magnification, which were filled with an array of 242 
cell debris and organelles (Figure 1J-L). 243 
Double immunofluorescence staining was carried out with anti-LC3B (an autophagy marker) and 244 
anti-LAMP1 (a major component of lysosomal membrane). In fibroblasts, fine dots of LC3B 245 
staining (green, Figure 1G) were observed and most of them were not colocalized with LAMP1 246 
(red, Figure 1G). Similar to fibroblasts, small dots of LC3B staining were observed in iPSC 247 
culture which were not co-localized with LAMP1. However, strong LC3B staining appeared in 248 
large vacuoles (green, Figure 1C) which co-localized with anti-LAMP1 staining, which could 249 
represent different status of LC3B activity. The control double staining were performed with 250 
anti-Syntaxin 6, a marker for Golgi membrane and MitoGreen for mitochondria (Figure 1D,H). 251 
As anticipated, they were no colocalization in either iPSCs (Figure 1D) or fibroblasts (Figure 252 
1H). These data therefore demonstrate that large autophagic vacuoles are a characteristic feature 253 
of iPSCs which harbor both LC3B-II and LAMP1.    254 
iPSCs exhibit higher abundance of LC3B-II than parental fibroblasts 255 
Next we compared iPSCs with parental fibroblasts from 4 independent donors by both 256 
immunocytochemtry (Figure 2a-D’) and immoblotting (Figure 2E-G). The immunofluorescence 257 
study showed brighter basal LC3B-II staining in iPSCs (Figure 2A-D) than in parental 258 
fibroblasts (Figure 2a-d). Rapamycin (100nM) induced autophagy in both iPSCs (Figure 2A’-D’) 259 
and fibroblasts (Figure 2a’-d’). Quantification of the immunoblots (Figure 2E) showed 2.55-fold 260 
higher basal LC3B-II in the iPSCs than that in parental fibroblasts (Figure 2F, p<0.01, n=4). 261 
After one day of Rapamycin induction at 100 nM, the LC3B-II was also 2.23-fold higher in the 262 
iPSCs than in fibroblasts (Figure 2G, p<0.05, n=4). Overall, these data show that autophagy is 263 
highly active in human iPSCs and is Rapamycin-inducible. Both the basal and induced 264 
autophagy are significantly higher in iPSCs than in dermal fibroblasts.  265 
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High basal levels of autophagy components are expressed in iPSCs 266 
To further address the autophagy activity during iPSC maintenance, we determined basal 267 
expression levels of 10 autophagy members involving different steps of autophagy. Autophagy is 268 
repressed by the mTOR and activated by Rapamycin. ULK1/2 are activated in a ULK1/2-269 
Atg13/101-FIP200 complex [23-24], which subsequently activates PI3K CIII complex 270 
(consisting of BECLIN-1, AMBRA, VPS34/15 and ATG14) and stimulates phagophore 271 
formation. ATG12 then conjugates with ATG5/16 and form phagophore [25]. ATG4/7/3 then 272 
converts LC3B-I to LC3B-II to form autophagic vacuole [17,22,26-27]. We extracted proteins 273 
from 12 iPSC lines derived from 10 independent donors (Figure 3), and carried out 274 
immunoblotting with antibodies against AMPK, ULK1, ULK2, ATG13, ATG101, BECLIN-1, 275 
ATG3, ATG5, ATG12 and LC3B. Relative protein abundance was quantified against house-276 
keeping proteins. AMPKα, BECLIN-1 ATG12, ATG13 and ULK1 were shown to be highly 277 
expressed in iPSCs, whereas ATG3, ATG101 and ULK2 were less abundant. No significant 278 
difference was detected among different lines for each component, but high levels of LC3B-II 279 
were detected in all iPSCs line (Figure 3A and 3C). To further evaluate the difference between 280 
iPSCs and fibroblasts, we investigated ATG5 and ATG12 expression among three fibroblast 281 
lines and 5 iPSC lines. The iPSCs were consistently showed to have much higher ATG5/ATG12 282 
expression compared to fibroblasts (Figure 3H). These data demonstrate that most autophagy 283 
components are abundantly expressed in iPSCs. 284 
Rapamycin induces iPSC autophagy in concentration- and time-dependent manners 285 
To determine if iPSC maintenance might benefit from upregulated autophagy, we investigated 286 
the dosage effect of Rapamycin on phosphorylated ULK1, p70S6K, and the autophagy indicator 287 
- ratio of LC3B-II/I. Both ULK1 and p70S6K are serine/threonine kinases and targets of mTOR. 288 
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p70S6K is a major regulator of translation and phosphorylated by mTOR [28-30], whereas 289 
ULK1 is an initiator of autophagy.  290 
We treated iPSCs with 0, 1, 10, 100, 200 or 300 nM of Rapamycin for 4 days, and observed a 291 
dose-dependent reduction in p70S6K phosphorylation (Figure 4I). The most significant reduction 292 
was achieved with 100-300 nM (Figure 4K). In contrast, LC3B-II (Figure 4J) and p-ULK1 293 
(Figure 4L) were enhanced in a dose-dependent manner, and the maximal increase was observed 294 
at 200 nM of Rapamycin (p<0.01). Similarly, immunostaining detected higher levels of LC3B-II 295 
expression in 200 nM Rapamycin-induced cells (Figure 4A-D).  296 
We then treated iPSCs with 200 nM of Rapamycin for 1, 3 and 6 days, observed significantly 297 
clustered LC3B-II staining after 3 days of Rapamycin treatment, and showed a time course-298 
dependent activation of autophagy (Figure 4E-H). This was different from fibroblasts, in which 299 
the total LC3B was increased by 24 hrs of Rapamycin treatment, whereas the LC3B-II remained 300 
relatively constant (supplement Figure 1). These data demonstrate that autophagy can be 301 
markedly activated by Rapamycin in iPSCs. 302 
Rapamycin attenuates Bafilomycin-induced iPSC death   303 
Bafilomycin A1 is an inhibitor of lysosome degradation by blocking the final stage of 304 
autophagy, fusion of autophagosomes with lysosome (31-32). We treated iPSCs with 0, 5, 50, 305 
100 nM of bafilomycin A1 for 24 or 48 hrs, with or without 200nM Rapamycin. Bafilomycin 306 
A1 was shown to induce iPSC death in concentration/time dependent manners. iPSC 307 
morphology was significantly altered after 24 hr of Bafilomycin treatment at 50 nM (Figure 308 
5) but not at 5 nM (Figure 5B). At 100 nM, Bafilomycin markedly induced iPSC death in 24 309 
hrs, leading to grossly reduced cell density after 48 hrs (Figure 5E). Addition of 200 nM 310 
Rapamycin significantly attenuated Bafilomycin-induced cell death, improved iPSC survival 311 
and increased iPSC cell density at 48 hrs Bafilomycin treatment (Figure 5G).  312 
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Western blotting showed that Bafilomycin enhanced both LC3B-I and -II bands by blocking 313 
basal autophagic flux. Rapamycin induced LC3B expression and caused a shift from LC3B-I 314 
to the LC3B-II (Figure 5H-I). Treatment of iPSCs with both Rapamycin and bafilomycin A1 315 
increased conversion of LC3B-II from LC3B-I similar to Rapamycin treatment alone, thereby 316 
attenuated bafilomycin-induced cell death (Figure 5C-D). These data further strengthen the 317 
importance of autophagy in iPSCs, as blockage of fusion of autophagosomes with lysosome 318 
rapidly induces iPSC death. Meanwhile addition of Rapamycin significantly improves the 319 
iPSC survival. 320 
Prolonged treatment with Rapamycin induces formation of uniform aggregates 321 
We next cultured iPSCs in geltrex-coated dishes in the presence of 200 nM of Rapamycin and 322 
examined the long-term effects on the maintenance of iPSCs. We first noticed the following 323 
morphological changes: (1) the peripheral cells of the iPSC colonies first started to elongate 324 
(Figure 6D) after 3 days, and cells at the edge produced an unknown matrix which formed a firm 325 
line at the border of colony after 6 days to limit iPSC colony expansion sideway (arrowheads, 326 
Figure 6F-G); (2) Rapamycin altered iPSC cell junctions, and cell borders became more obvious 327 
after 2 days of treatment (Figure 6C-D); and (3) iPSCs continued to proliferate in the central 328 
areas of colonies, together with the limitation to expand sideway and reduced cell-cell contacts, 329 
round EB-like spheres were formed and detached from the culture dish before and after 6 days of 330 
Rapamycin treatment (*, Figure 6E-F). 331 
The average aggregate size at 6 days was 64793±18779 µm2 (n=13). The round spheres 332 
continued to detach and grow after 9 days of treatment, and reached the sizes of 112251±17422 333 
(002V, n=8), 104640±27265 (JOM, n=13), 105381±13468 µm2 (LV1, n=7) in three independent 334 
iPSC lines, respectively. However, the control EBs resulted from the cut-and-paste method 335 
varied significantly in shape and sizes (Figure 7F-H). They were 52328±25518 (002V, n=10); 336 
80518±77708 (JOM, n=20); 75652±51944 µm2 (LV1, n=22), respectively, and displayed 337 
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consistently large variation (SD) in sizes within each line (Figure 7B). These data show that high 338 
concentrations of Rapamycin treatment can induce iPSC detachment and spontaneous formation 339 
of uniformly sized aggregates. 340 
Rapamycin treatment accelerates differentiation of human iPSCs 341 
To determine the nature of the floating spheres resulting from Rapamycin treatment, we 342 
extracted proteins from the aggregates and compared them with EBs generated via the cut-and-343 
paste method by immunoblotting with three germ layer markers of α-fetoprotein (AFP for 344 
endoderm), α-smooth muscle actin (ASM for mesoderm), and βIII tubulin (TUJ1 for ectoderm), 345 
together with autophagy marker LC3B-II (Figure 8A). The expression of these marker proteins 346 
was 2~3 fold higher in the Rapamycin-induced spheres (Figure 8A-C). 347 
To examine differentiation potential of aggregates, we plated them out for spontaneous 348 
differentiation and compared with EBs made mechanically. Cells with neuronal morphology 349 
appeared after 3 days without neuronal induction (Figure 8J-L), and many were stained positive 350 
for neural stem cell marker NESTIN (Figure 8M). After 5 days of spontaneous differentiation, 351 
we carried out immunocytochemical staining with AFP, ASM, TUJ1, and obtained significantly 352 
higher proportions of cells positive for these makers in cells derived from Rapamycin-induced 353 
spheres (Figure 8G-I), compared with cells differentiated from the conventional EBs (Figure 8D-354 
F). To illustrate mechanism(s) of Rapamycin-induced iPSC differentiation, we investigated 355 
NANOG expression after 4 days of treatment by immunoblotting (Figure 8L). Rapamycin was 356 
shown to down-regulate NANOG expression in a concentration-dependent manner, and 357 
significant reductions were detected at 100 nM (p<0.05), 200 nM (p<0.01) or 300 nM of 358 
Rapamycin treatment (p<0.01, Figure 8M). These data suggest that Rapamycin-induced spheres 359 
are similar to conventional EBs in pluripotency of differentiation, they are non-biased in 360 
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differentiating into three lineages, but differentiate in an accelerated pace, in association with 361 
down-regulated NANOG expression during EB formation. 362 
Rapamycin regulates adherens junctions and actin cytoskeleton in human iPSCs 363 
To identify potential molecular mechanisms associated with Rapamycin-induced iPSC 364 
detachment, we performed quantitative mass spectrometry analysis with proteins extracts from 365 
control iPSCs and iPSCs treated with 50, or 100 nM of Rapamycin for 3, 6, 9 days respectively 366 
(n=3 for each). A total of 6145 proteins were quantitatively identified, and 220 proteins were 367 
identified by statistical analyses, which were systematically altered at different time points and at 368 
both Rapamycin concentrations (One-way ANOVA, two-tailed, p<0.05). Gene ontology (GO) 369 
analyses of the 220 targets with the STRING database revealed that adherens junctions (17 hits, 370 
p=6.49x10-6) and actin cytoskeleton (9 hits, p=0.022) were significantly enriched in the 371 
Rapamycin-treated cells (Figure 9), which integrated into an interactive network (Figure 9F). 372 
Of the 17 adherens junction molecules, 9 (ACTN4, BSG, EPHA2, EZR, FLNB, PDLIM1, PPIA, 373 
SHROOM3, RPLP0) were down-regulated, and 8 (ABI2, GSN, ACTR3, ARF6, RALA, RPL7A, 374 
RPL19, RPL27) were up-regulated (Figure 9A-C). Of the 9 actin cytoskeleton associated 375 
proteins, 6 (ACTN4, CGN, EZR, FGD4, SERPINA3, TTN) were down-regulated and 3 376 
(CTTNBP2NL, GSN, SEPT11) were up-regulated (Figure 9D-E). In consistent with the 377 
morphological changes, these data suggest that alterations of adherens junctions and 378 
cytoskeleton are the key pathways in Rapamycin-induced iPSC behavior.  379 
 380 
Discussion 381 
Autophagy is a cellular mechanism to maintain minimal cell activity for viability in response to 382 
nutrient limitations and cell stress, by degrading and recycling cytoplasmic proteins and 383 
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subcellular organelles via the fusion of a double-membrane-bound vesicle, autophagosome, with 384 
lysosome [17,33]. Autophagy plays an essential role in cellular reprogramming and basal level of 385 
autophagy increases in aging human skin fibroblasts, which may affect to different 386 
reprogramming efficiency [34]. It appears there is no co-relation with sex (all male) or age (4-387 
20-year) in the fibroblast lines we have used, but with heath status, which requires validation in 388 
larger sample sets. In this study we demonstrate abundant presence of large autophagic vacuoles 389 
in early fibroblast reprogramming and smaller ones during the iPSC maintenance. We show high 390 
basal level of key components of autophagy in 12 iPSC lines derived from 10 independent 391 
donors, and prolonged Rapamycin treatment resulted spontaneous formation of uniformed sized 392 
EBs with accelerated differentiation pace.  393 
In previous studies, lack of autophagy components of Atg3, or Atg5 or Atg7 was shown to 394 
render MEF cells defective in iPSC colony formation [15], and lack of two different autophagy 395 
genes, atg5 and beclin1, displayed a defect in EB formation during development [35]. The 396 
reprogramming was entirely blocked also in Tsc2-/- somatic cells with hyperactivated mTOR 397 
activity which suppressed autophagy [14]. Subtle tuning of the mTOR activity with inhibitors, 398 
i.e. 0.3-1 nM Rapamycin or 0.1 nM PP242 was found to increase reprogramming efficiency [18]. 399 
Mechanistically, the reprogramming factor Sox2 could bind to mTOR promoter and repress 400 
mTOR expression and activate autophagy [15]. These data together showed that reduced mTOR 401 
activity and elevated Autophagy were required during cellular reprogramming, which is 402 
consistent with our observation that abundant large autophagic vacuoles are present in early 403 
fibroblast reprogramming, which become smaller during the subsequent passaging. 404 
A balanced autophagy and mTOR activity is also essential for the maintenance and 405 
differentiation of pluripotent stem cells. Human ES cells were previously shown to have a tight 406 
regulation of the mTOR signaling to mediate protein translation for maintaining the pluripotent 407 
status [36]. Activation of p70S6K, a mTOR downstream factor, was shown to induce 408 
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differentiation of human ES cells [36], whereas inhibition of mTOR autophosphorylation by 20 409 
nM Rapamycin was reported to disrupt p70S6K-mediated translation, but not to alter cell 410 
viability or expression of the pluripotency markers [37]. In contrast, the mTOR was necessary 411 
for growth and proliferation of early mouse embryos and ES cells, and disruption of the mouse 412 
mTOR gene prohibited ES cell development [38-39]. Interestingly, 100nM Rapamycin was 413 
previously shown to reduce the size and rate of EB formation in human amniotic fluid stem cells 414 
[40]. This was different from our study that high concentration of Rapamycin induced EB 415 
formation in iPSCs. Inhibition of the mTOR activity with high concentrations of Rapamycin also 416 
greatly impaired somatic cell reprogramming [14], and 100 nM Rapamycin was used to primer 417 
hepatocyte differentiation of iPSCs prior to Activin A induction [41]. This is consistent with our 418 
data that Rapamycin down-regulates NANOG expression in a concentration dependent manner 419 
and accelerates iPSC differentiation. 420 
To uncover Rapamycin pathways in iPSCs, we carried out quantitative mass spectrometry. The 421 
STRING Gene Ontology analyses revealed that actin cytoskeleton and adherens junctions were 422 
the integrated pathways regulated by Rapamycin. For example, ACTN4, BSG, CGN, EPHA2, 423 
EZR, FGD4, FLNB, PDLIM1, PPIA, SHROOM3, RPLP0, SERPINA3 and TTN were 424 
significantly down-regulated, whereas ABI2, CTTNBP2NL, GSN, ACTR3, ARF6, RALA, 425 
RPL7A, RPL19, RPL27 and SEPT11 were up-regulated.  426 
Actin is critical for cell shape, adhesion and migration. The dynamics of actin cytoskeleton are 427 
modulated by Rapamycin targets of SHROOM3, EZR and GSN. For example, SHROOM3 is 428 
required for the apical localization of F-actin/myosin II [42]. EZR links the plasma membrane to 429 
actin and is involved in adhesion and migration. Inhibition of EZR expression reduced 430 
adhesiveness in colorectal cancer cells [43]. GSN knockdown decreased cell viability and tumor 431 
cell invasion, whereas GSN overexpression correlates with proliferative and invasive capacities 432 
[44]. BSG promotes cell–cell adhesion, and its down-regulation altered actin/Spectrin network 433 
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[45]. Therefore, reduced expression of SHROOM3, EZR and BSG in the Rapamycin-treated 434 
iPSCs is in line with reduced cell adhesion in the literature. 435 
ACTN4, FLNB, PDLIM1 are actin-binding proteins. ACTN4 is concentrated at sharp extension 436 
and at the edge of cell clusters [46], and FLNB regulates direct communication between the cell 437 
membrane and cytoskeletal network [47]. PDLIM1 function as an adapter to recruit other LIM-438 
interacting proteins to the cytoskeleton, and suppression of PDLIM1 resulted in cell spreading 439 
and the loss of stress fibers and focal adhesions [48]. In addition, ACTR3 is also essential to cell 440 
shape and motility, and is an ATP-binding component of the ARP2/3 complex, which regulates 441 
actin polymerization. The complex can be activated by ABI, and knockdown of ABI markedly 442 
inhibits cell-cell junctions [49]. Therefore, Rapamycin-induced changes in the expression of 443 
ACTN4, ACTR3, FLNB and PDLIM1 are also likely to affect actin cytoskeleton. 444 
Some of Rapamycin targets are GTPase activity-related, such as downregulated EPHA2 and 445 
upregulated ARF6 and RALA. GTPases are involved in cell adhesion migration and oncogenic 446 
transformation. For example, EphA2 is a transmembrane receptor tyrosine kinase activating and 447 
prompts cells to round up and detach from their neighbors [50]. RALA is a small GTPase and 448 
constitutively active RALA promotes anchorage-independent growth signaling [51]. ARF6 is a 449 
small GTPase to balance with RAB35 GTPase by cells during cell migration and adhesion. 450 
Increased ARF6 activity from RAB35 knockdown enhances cadherins accumulation and reduces 451 
cell–cell adhesion. The loss of RAB35, However, correlates with enhanced cell migration [52]. 452 
Therefore, reduced EPHA2 and increased ARF6 and RALA expression may also contribute to 453 
Rapamycin-induced iPSC detachment. Together these data showed that Rapamycin regulates an 454 
array of adherens junctions and actin modifying molecules, which collectively alters iPSC 455 
adhesion.  456 
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Conclusions 458 
In this study, we demonstrate that autophagy is a prominent feature of reprogramming cells 459 
and stable iPSCs. The basal level of autophagy is universally present among human iPSC 460 
lines, which is significantly higher than parental fibroblasts. Block of autophagy by 461 
Bafilomycin induces iPSC death. Rapamycin activates autophagy in concentration- and time-462 
dependent manners and attenuate Bafilomycin toxicity in iPSCs. Prolonged Rapamycin 463 
treatment induces cell detachment and formation of uniformly sized EBs from human iPSCs, 464 
with altered expression of adherens junctions and actin modifying molecules. The Rapamycin 465 
downregulates NANOG expression, induces EBs formation and accelerates cell 466 
differentiation into three germ layer lineages. This findings are significant in two-fold. 467 
Firstly, the 3D microenvironment including shape and sizes of EBs can affect differentiation. 468 
The iPSCs are supersensitive to enzyme dissociation and therefore the “hanging drop” 469 
technique is difficult to apply, despite it was available to generate uniform EBs from ES cells 470 
over 20 years ago. Rapamycin may therefore assist generation of uniformly sized EB with 471 
round shape which may reduce the heterogeneity of the end cell types. Secondly, 472 
differentiation of mature and functional cell types from human iPSCs is time-consuming, and 473 
the accelerated differentiation associated with Rapamycin treatment is promising in 474 
shortening the differentiation duration. Rapamycin, therefore, may find its application in 475 
assistance of overcoming the challenges associated with phenotypic characterization, drug 476 
discovery and cell replacement therapy for neurological disorders.  477 
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 680 
Figure legends  681 
Figure 1. Autophagy machinery is widely operated in iPSCs. (A) Images of cells were taken at 682 
day 15 of fibroblast reprogramming and large autophagic vauoles were arrowheaded. (B) 683 
Smaller autophagic vacuoles (arrowheaded) were observed in stable iPSC lines with daily 684 
change of culture medium. (C-D,G-H) Double immunofluorescence staining of iPSCs (C-D) and 685 
fibroblasts (G-H) was carried out with anti-LC3B for autophagy (C,G, green) and anti-LAMP1 686 
for lysosome (C,G, red), Syntaxin 6 for Golgi membrane (D,H, red) and MitoGreen (D, H, 687 
green) for mitochondria, with counter-staining of DAPI (blue) for nuclei. Fluorescent images 688 
were acquired via confocal microscopy. Note that LC3B and LAMP1 are colocalized in iPSCs 689 
(C) but not in fibroblasts (G), whereas Syntaxin 6/MitoGreen are not colocalized as anticipated 690 
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(D,H).  (E, I-L) Transmission electronic microscopic images showed a dead neucleus (*, A and 691 
E), lysosomal structures (blue arrowheads, E,I), and autophagic vacuoles (red arrowheads, J-L). 692 
Bars=20 µm in A-D and F-H; 10 µm in E and I; 500 nm in J-L. 693 
 694 
Figure 2. iPSCs exhibit higher autophagy activity than parental fibroblasts. Fibroblasts (a-d, a’-695 
d’) and iPSCs (A-D, A’-D’) derived from 4 independent donors were culture in the absence (-R) 696 
or presence (+R) of 100nM Rapamycin for 24 hours. The iPSCs showed higher basal staining of 697 
LC3B (A-D) than in parental fibroblasts (a-d). LC3B was highly induced by 100 nM of 698 
Rapamycin in iPSCs (A’-D’), with lower levels of induction in their respective fibroblasts (a’-699 
d’). Fluorescent images were acquired via confocal microscopy. Bar=10 µm. (E) Immunoblots of 700 
the protein extracts from untreated (-R) or treated (+R) cells with anti-LC3B-II and anti-β-701 
ACTIN. (F-G) The relative abundance of LC3B-II was quantified using ImageJ and data were 702 
presented with Mean ± SD. (F) The basal level of LC3B-II in the iPSCs was 2.55-fold higher 703 
than in parental fibroblasts (**, p<0.01, n=4). (G) Rapamycin-induced expression of LC3B-II in 704 
the iPSCs was also 2.23-fold higher than fibroblasts (*, p<0.05, n=4).  705 
 706 
Figure 3. Wide expression of different autophagy components in independent iPSC lines. 707 
Proteins were extracted from iPSCs with daily renewal of culture medium. 15 µg of protein was 708 
loaded onto each lane. Lane a-l represents 12 independent iPSC lines from 10 donors (a, 33D6; 709 
b, JOM; c, LV1; d, LV2; e, LV3; f, 001CC1; g, NRXN1C1; h, 002V; I, 003V; j, SC126; k, 710 
SC128, l, SC132). (A-C) Immunoblotting was carried out with antibodies against LC3B-I, 711 
LC3B-II, BECLIN-1, AMPK, ULK1, ULK2, ATG3, ATG12, ATG13, ATG101 and β-Actin. 712 
(D-G) The relative abundance of the proteins was quantified using ImageJ against β-Actin and 713 
data were presented with Mean ± SD. (H) Immunoblots were carried out to compare expression 714 
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of ATG5 and ATG 12 among 3 fibroblast lines (3x Fib.) and 5 iPSC lines (5xiPSCs) of healthy 715 
donors, showing higher ATG5 and ATG12 expression in iPSCs than that in fibroblasts. 716 
 717 
Figure 4. Rapamycin induces autophagy in time- and concentration-dependent manners in 718 
iPSCs. iPSCs were maintained in 6-well plates and medium was renewed daily. Image of LC3B 719 
staining in panels A-D were taken from 4 days of Rapamycin treatment at 0, 10, 100 or 200 nM 720 
respectively, and image in panels E-H were sampled from 200 nM of Rapamycin treatment for 1, 721 
3 and 6 days respectively, showing concentration- and time-dependent induction. (I) Proteins 722 
were extracted from iPSCs treated with Rapamycin at 0, 1, 10, 100, 200 or 300 nM for 4 days, 723 
and immunobloted with antibodies against LC3B, phosphorylated ULK1, phosphorylated p70 724 
S6K or β-Actin. (J-L) The relative abundance of the LC3B-II/I ratios (J), p-p70S6K (K) and p-725 
ULK1 (L) was quantified using ImageJ against a loading control β-Actin. Data were presented 726 
with Mean ± SEM, with * for p<0.05, and ** for p <0.01. Bars = 10µm in A-H. 727 
 728 
Figure 5. Rapmycin attenuates Bafilomycin A1-induced iPSC death. iPSCs were treated with 729 
0 (A), 5nM (B) , 50 nM (C) , 100 nM  (D,E) of Bafilomycin for 24 (A-D) or 48 hours (E). 730 
Bafilomycin A1 induced cell death in a concentration dependent manner (A-D), leading to 731 
substantial cell loss after 48 hours at 100 nM (D). Addition of 200 nM Rapamycin attenuate 732 
Bafilomycin A1-induced cell death and maintained iPSC normal cell density (F,G). (H) Anti-733 
ACTIN and Anti-LC3B immoblotting were carried out with iPSC lysates from control iPSCs 734 
(Con), or 24 hour of treatment with 200 nm of Rapmycin (Rap), or with 100 nM of Bafilomycin 735 
A1 (Baf) or with both (Rap+Baf). (I) The relative abundance of the LC3B-II/I ratios was 736 
quantified against a loading control β-ACTIN. Data were presented with Mean ± SEM, with * 737 
for p<0.05, and ** for p <0.01, n = 4. Bar=50 µm in A-B. 738 
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Figure 6. A time course of Rapamycin-induced cell detachment and EB formation. iPSCs were 740 
cultured in the presence of 200 nM Rapamycin. Bright field microscopic images were taken after 741 
1 (B), 2 (C), 3 (D) and 6 (E-F) days of treatment. EB-like spheres were spontaneously formed 742 
after 6 days of Rapamycin treatment. Arrowheads in C, E and F indicated the border of the iPSC 743 
colonies which formed a line after day 6 to limit colony expansion sideway. (E) * indicated the 744 
areas of iPSC detachment, which were filled with a thin layer of iPSCs. (F) Four EB-like spheres 745 
of comparable size were captured in the fields. (G) Magnified view (4x) of the border area 746 
arrowheaded in image F. Bar=100 µm in A-D, 200 µm in E-F. 747 
 748 
Figure 7. Rapamycin induces spontaneous formation of uniform sizes of EBs. (A-C) Images of 749 
floating spheres appeared after 9 days of Rapamycin treatment (200 nM) from 3 iPSC lines. (D-750 
F) Images of EBs made after 9 days from “cut-and-paste” method. (G) The EB area sizes (µm2) 751 
were quantified with ImageJ and data were presented with Mean ± SD. Note the round shape and 752 
uniform sizes of EBs from Rapamycin treatment (A-C), in contrast to irregular shape and sizes 753 
of EBs resulted from the same iPSC lines by mechanical method (D-F). Bar = 200 µm. 754 
 755 
Figure 8. Rapamycin treatment accelerates differentiation of human iPSCs in association with 756 
decreased NANOG expression. (A) Proteins were extracted from Rapamycin-induced spheres 757 
and control EBs, and blotted with antibodies against LC3B, AFP, ASM, TUJ1 and β-ACTIN. (B) 758 
Relative protein expression was quantified against β-ACTIN, (C) compared between two 759 
methods, and presented as M ± SEM. Note a 2~3 fold increase of LC3B, AFP, ASM, and TUJ1 760 
expression in Rapamycin-induced spheres. Rapamycin-induced spheres and control EBs were 761 
plated out for spontaneous differentiation for 3 days (J-K) or 5 day (D-I), and stained for 762 
NESTIN (M), TUJ1 (D, G), ASM (E, H), AFP (E, I). Note the presence of more immune-763 
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positive cells in derivatives of Rapamycin-induced spheres (G-I) compared with cells 764 
differentiated from conventional EBs (E-F). (L) Proteins were extracted from iPSCs treated with 765 
Rapamycin at 0, 1, 10, 100, 200 or 300 nM for 4 days, and immunobloted with anti-NANOG, 766 
showing concentration-dependent reduction of NANOG expression after Rapamycin treatment. 767 
(M) Relative abundance of NANOG expression after 4 days of Rapamycin treatment. Bar = 100 768 
µm in D-I; Bar = 50 µm in J-K. * for p<0.05, and  ** for p<0.01. 769 
 770 
Figure 9. Rapamycin regulates adherens junctions and actin cytoskeleton pathways in iPSCs. 771 
Three independent lines of iPSCs were maintained in mTeSR™ (con) or in the presence of 50 or 772 
100nm Rapamycin for 3, 6 or 9 days. Proteins were harvested for Mass Spectrometry analyses. 773 
(A-E) The time course changes of protein expression (mean±SEM, n=3). * for p<0.05. (F) The 774 
molecular network for selected proteins whose expression was altered. The data show the 775 
network of interactions between adherens junctions and actin signaling by the STRING. The 776 
arrows indicated up- or down-regulation of the protein expression after Rapamycin treatment. 777 
 778 
Supplemental Figure 1. Rapamycin induces LC3B expression in human fibroblasts. Three 779 
lines of human fibroblasts (F1, F2, F3) were treated without (-) or with (+) 100 nM Rapamycin 780 
overnight. The protein lysates were run of 15% SDS-PAGE and blotted with anti-LC3B and anti-781 
GAPDH. Two bands of LC3B-I (16kD) and LC3B-II (14kD) were seen. Rapamycin is shown to 782 
induce LC3B-I expression after 24 hours of treatment.  783 
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Submission of Revised Manuscript: “Rapamycin Regulates Autophagy and Cell Adhesion 
in Induced Pluripotent Stem Cells”  
Dear Editor, 
We thank you very much for your kind invitation. We have done additional experiments to carry out a 
comprehensive revision for the manuscript “Rapamycin Regulates Autophagy and Cell Adhesion 
in Induced Pluripotent Stem Cells” by Sotthibundhu et al, with point-to-point response to address 
Reviewers’ constructive comments. The texts are revised accordingly with key revision data including: 
Figure 1: we have provided fibroblasts image in Figure 1F and double staining images in Figure 1C.D.G.H. 
Figure 3: we have supplied comparison with fibroblasts in Figure 3H by immunoblotting. 
Figure 5: we added new Bafilimycin treatment data Figure 5A-I. 
Figure 7: we removed duplicated image in Figure 7. 
Figure 8: we removed duplicated images and supplied new mechanistic data of NANOG expression in Figure 
8L-M.  
Supplemental Figure 1: Immunoblotting of fibroblasts for LC3B expression. 
 
We hope the revised manuscript has addressed major concerns and comments in the previous review process. 
We will be delighted to hear if the manuscript has now reached the standard of SCRT for publication. 
 
Kind regards 
 
Sanbing Shen, PhD 
Professor of Fundamental Stem Cell Biology,  
Regenerative Medicine Institute,  
School of Medicine, National  
University of Ireland Galway (NUI) Ireland.  
Tel: 00-353-91-494261 (office).  
Email: sanbing.shen@nuigalway.ie. 
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